As you know, President Trump issued three executive orders implementing tariffs on February 1 on virtually all goods from China, Mexico, and Canada, which have now been paused for thirty days in the case of Mexico and Canada. We are partnering with our customers to understand the impacts and to determine the best solutions in the short term and the long term for their supply chains. Our Mexico facility exports approximately 25% to 30% of its production into the United States. Our US facilities import certain components from China, Mexico, and Canada on our customers' behalf to use in manufacturing their products. There are a variety of options we will continue to review with our customers. Our customers may be able to change Kimball's final delivery location, shift production to another Kimball facility, or pay the tariffs. We are also evaluating the impact on our supply chains, including the goods we import into the US that support manufacturing in our US locations. As you would expect, given our guiding principles and our reputation for customer service, Kimball stands ready to support our overall supply chain and our customers as they navigate these significant developments. Lastly, I'd like to recognize our team for once again being honored by Circuit's Assembly Service Excellence Awards. In November, we achieved the highest overall customer ratings in all seven categories, of dependability and timely delivery, manufacturing quality, responsiveness, technology, value for the price, flexibility, and overall satisfaction. These awards are based solely on direct customer input, and I'm very proud of our team's consistent focus on building long-term relationships with all customers regardless of whether they are new, or those we've worked with for a decade or more. The Kimball team is well known for our culture driven by our guiding principles and a common set of priorities that have allowed us to continuously improve and to keep our promises. Even during the most challenging of times. With customer demand continuing to soften in the markets we support, and the timing of a recovery in our core EMS business becoming increasingly more difficult to predict and likely continuing through calendar year 2025. We have intensified our efforts to broaden our capabilities and role as a CMO. With a strong balance sheet, pursuing different paths of growth, focused on emerging medical technologies, high-level assemblies, and a variety of drug-device combinations. As I mentioned earlier, however, these changes will not come overnight. But I'm excited for the future of the company, and thank you for your support. Daryl, we would now like to open the lines for questions.